nach oben

Digestive Diseases and Sciences

Erschienen in:

20.09.2022 | Multicenter Seminars: IBD (MUSE: IBD)

An Old Bridge to the Newer Biologics: Cyclosporine for Rescue Therapy in Acute Severe Ulcerative Colitis

verfasst von: Divya Ashat, Animesh Jain, Kimberly N. Weaver, Millie D. Long, Hans H. Herfarth, Edward L. Barnes

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Excerpt

A 45-year-old man with an 11-year history of extensive ulcerative colitis (UC) was evaluated for acute severe UC (ASUC), manifest as increased stool frequency, urgency, hematochezia, and left-sided abdominal pain. He had previously been well-controlled with vedolizumab infusions every 4 weeks for 2 years, but he self-discontinued this therapy in the setting of clinical and endoscopic remission. Therapies utilized prior to vedolizumab included infliximab and azathioprine combination therapy (initiated during a prior admission for ASUC) that were discontinued due to loss of insurance. …

Loftus CG, Egan LJ, Sandborn WJ. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin N Am 2004;33:vii.

Rubin DT, Ananthakrishnan AN, Siegel CA et al. ACG Clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019;114:384–413.CrossRefPubMed

Barberio B, Black CJ, Savarino EV, Ford AC. Ciclosporin or infliximab as rescue therapy in acute glucorticosteroid-refractory ulcerative colitis: systematic review and network meta-analysis. J Crohns Colitis 2021;15:733–741.CrossRefPubMed

Szántó K, Molnár T, Farkas K. New promising combo therapy in inflammatory bowel diseases refractory to anti-TNF agents: cyclosporine plus vedolizumab. J Crohns Colitis 2018;12:629.CrossRefPubMed

Christensen B, Gibson PR, Micic D et al. Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease. Clin Gastroenterol Hepatol 2019;17:486–493.CrossRefPubMed

Pellet G, Stefanescu C, Carbonnel F et al. Efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab in patients with refractory ulcerative colitis. Clin Gastroenterol Hepatol 2019;17:494–501.CrossRefPubMed

Ollech JE, Dwadasi S, Rai V et al. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2020;51:637–643.CrossRefPubMed

Resál T, Pigniczki D, Szántó K et al. Letter: ciclosporin and vedolizumab for steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2020;52:578–579.CrossRefPubMed

Ganzleben I, Geppert C, Osaba L et al. Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis. Therap Adv Gastroenterol 2020;13:1756284820954112.CrossRefPubMedPubMedCentral

10.

Shaffer SR, Traboulsi C, Krugliak Cleveland N, Rubin DT. Combining cyclosporine with ustekinumab in acute severe ulcerative colitis. ACG Case Rep J 2021;8:e00604.CrossRefPubMedPubMedCentral

11.

Lichtenstein GR, Loftus EV, Isaacs KL et al. ACG Clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 2018;113:481–517.CrossRefPubMed

12.

Feagan BG, Lasch K, Lissoos T et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2019;17:130-138.e137.CrossRefPubMed

13.

Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology 2020;158:1465-1496.e1417.CrossRefPubMed

14.

Click B, Regueiro M. A practical guide to the safety and monitoring of new IBD therapies. Inflamm Bowel Dis 2019;25:831–842.CrossRefPubMed

15.

Weisshof R, Ollech JE, El Jurdi K et al. Ciclosporin therapy after infliximab failure in hospitalized patients with acute severe colitis is effective and safe. J Crohns Colitis 2019;13:1105–1110.CrossRefPubMedPubMedCentral

Titel: An Old Bridge to the Newer Biologics: Cyclosporine for Rescue Therapy in Acute Severe Ulcerative Colitis
verfasst von: Divya Ashat
Animesh Jain
Kimberly N. Weaver
Millie D. Long
Hans H. Herfarth
Edward L. Barnes
Publikationsdatum: 20.09.2022
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 12/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-022-07682-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

An Old Bridge to the Newer Biologics: Cyclosporine for Rescue Therapy in Acute Severe Ulcerative Colitis

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2022

Evaluation of a Multidisciplinary Integrated Treatment Approach Versus Standard Model of Care for Functional Gastrointestinal Disorders (FGIDS): A Matched Cohort Study

Empirical Dilation of Non-obstructive Dysphagia: Current Understanding and Future Directions

Relationships of Intestinal Lactase and the Small Intestinal Microbiome with Symptoms of Lactose Intolerance and Intake in Adults

Hiding in Planus Sight: Localized Ulcerative Jejunitis in a Patient with Celiac Disease

Endoscopic Balloon Dilation Is Cost-Effective for Crohn’s Disease Strictures

EUS-Guided Hepatico-Gastrostomy: To Dilate or Not to Dilate?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin